We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+12.43%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$6.26M
Cap. Flow
-$20.2M
Cap. Flow %
-6.04%
Top 10 Hldgs %
55.99%
Holding
67
New
24
Increased
10
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$12.9M
2
INCY icon
Incyte
INCY
+$8.26M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$8.02M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.82M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$7.23M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.4M
2
ACLX
Arcellx
ACLX
+$14.7M
3
IMCR icon
Immunocore
IMCR
+$11.5M
4
MRK icon
Merck
MRK
+$10.2M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.46B
$4.2M 1.26%
132,703
+30,916
+30% +$1.17M
TERN
27
DELISTED
Terns Pharmaceuticals
TERN
$3.75M 1.12%
+449,321
New +$3.7M
CATX icon
28
Perspective Therapeutics
CATX
$336M
$3.18M 0.95%
238,084
-105,726
-31% -$1.41M
PYXS icon
29
Pyxis Oncology
PYXS
$141M
$3.12M 0.93%
850,210
-352,465
-29% -$1.23M
NGNE icon
30
Neurogene
NGNE
$728M
$3.08M 0.92%
73,299
-5,302
-7% -$206K
URGN icon
31
UroGen Pharma
URGN
$1.95B
$3.07M 0.92%
+241,984
New +$3.59M
VIGL
32
DELISTED
Vigil Neuroscience
VIGL
$2.53M 0.76%
743,719
-693
-0.1% -$2.57K
WVE icon
33
Wave Life Sciences
WVE
$1.09B
$2.46M 0.74%
+300,000
New +$1.79M
BBIO icon
34
BridgeBio Pharma
BBIO
$15.7B
$2.42M 0.72%
+94,885
New +$2.49M
JANX icon
35
Janux Therapeutics
JANX
$966M
$2.24M 0.67%
49,415
-43,534
-47% -$1.89M
SRZN icon
36
Surrozen
SRZN
$241M
$2.19M 0.66%
182,918
+39,408
+27% +$348K
RYTM icon
37
Rhythm Pharmaceuticals
RYTM
$7.28B
$2.16M 0.65%
+41,268
New +$1.98M
BBOT
38
BridgeBio Oncology
BBOT
$666M
$2.09M 0.63%
200,000
– –
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.82B
$1.88M 0.56%
+15,014
New +$2.08M
TARA icon
40
Protara Therapeutics
TARA
$229M
$1.73M 0.52%
942,857
-41,256
-4% -$84.7K
PCSC
41
Perceptive Capital Solutions
PCSC
$124M
$1.5M 0.45%
150,000
– –
TRML
42
DELISTED
Tourmaline Bio
TRML
$1.43M 0.43%
+55,523
New +$927K
CAPR icon
43
Capricor Therapeutics
CAPR
$1.11B
$1.42M 0.43%
+93,638
New +$463K
ALKS icon
44
Alkermes
ALKS
$8.66B
$1.37M 0.41%
+48,918
New +$1.3M
CNTA
45
DELISTED
Centessa Pharmaceuticals
CNTA
$1.34M 0.4%
+83,662
New +$1.02M
MBX
46
MBX Biosciences
MBX
$2.78B
$1.3M 0.39%
+50,000
New +$1.14M
CYTK icon
47
Cytokinetics
CYTK
$10.9B
$764K 0.23%
+14,464
New +$806K
RVMD icon
48
Revolution Medicines
RVMD
$38.1B
$755K 0.23%
+16,654
New +$725K
ATXS
49
DELISTED
Astria Therapeutics
ATXS
$619K 0.19%
+56,287
New +$626K
EWTX icon
50
Edgewise Therapeutics
EWTX
$4.11B
$531K 0.16%
19,900
-251,157
-93% -$5M
1
2
3

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Stempoint Capital held 67 positions worth $334M, down 1.8% from $340M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Stempoint Capital withdrew a net $20.2M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Immunocore, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Bristol-Myers Squibb worth $14.2M.

  • Stempoint Capital's largest Q3 2024 buy was Bristol-Myers Squibb: 275,303 shares worth $14.2M.
  • Stempoint Capital added most to Arcutis Biotherapeutics in Q3 2024, an estimated $8.02M increase.
  • Stempoint Capital's biggest Q3 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $17.4M.
  • Stempoint Capital fully exited Immunocore in Q3 2024, selling an estimated $11.5M.
  • Stempoint Capital's ten largest holdings make up 56% of its $334M portfolio in Q3 2024.
  • Stempoint Capital opened 24 new positions and closed 13 in Q3 2024.
  • Stempoint Capital's portfolio value fell 1.8% quarter-over-quarter to $334M.

Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.